Explore BioBoost LabsFOXO4-DRI
A designed D-retro-inverso peptide built to disrupt the FOXO4-p53 interaction in senescent cells.
What the name means
“FOXO4” names the target: the transcription factor Forkhead box O4. “DRI” stands for D-retro-inverso, a specific peptide-engineering strategy.
Together the name describes a D-retro-inverso peptide modeled on part of the FOXO4 protein.
What it actually is
FOXO4-DRI is a synthetic peptide based on a segment of FOXO4 that contacts the tumor-suppressor protein p53. In a D-retro-inverso design the sequence is reversed and built from D-amino acids rather than the usual L-amino acids.
The retro-inverso approach aims to preserve a similar arrangement of side chains to the natural segment while making the peptide more resistant to breakdown by proteases; the exact designed sequence is documented in the primary research literature.
Where it came from
FOXO4-DRI was introduced by Peter de Keizer and colleagues in a 2017 study in the journal Cell (Baar and colleagues) on targeting senescent cells.
It arose from work on cellular senescence, the state in which damaged cells stop dividing but persist, and on how FOXO4 helps such cells keep p53 in check to avoid self-destruction.
Why it was created — the thought process
The design rationale was to selectively remove senescent cells. In those cells, FOXO4 was reported to bind p53 and hold it away from the machinery that would otherwise trigger cell death.
By occupying that interaction, FOXO4-DRI was intended to release p53 in senescent cells and push them toward apoptosis while sparing healthy cells, an approach known as senolysis. The D-retro-inverso format was chosen for stability.
How it is made
FOXO4-DRI is produced by solid-phase peptide synthesis using D-amino acids assembled in the reversed order dictated by the retro-inverso design.
It is then purified by HPLC and confirmed by mass spectrometry. Using D-amino acids requires the corresponding D-configured building blocks but otherwise follows standard synthetic peptide chemistry.
What the research actually shows — honestly
Evidence for FOXO4-DRI comes primarily from cell-culture and mouse studies, where it has been used as a research tool to probe senescence.
It has not been established as an effective or safe treatment in humans, and senolytic peptide approaches remain an active, unsettled area of investigation. FOXO4-DRI is supplied for research use only (RUO) and is not an approved drug for human or veterinary use.
Selected research & sources
The items below are drawn from the peer-reviewed literature (PubMed) and describe results observed in research models or reported in the clinical literature. They are listed so the evidence can be examined at its source — not to suggest any use.
- Meng J, et al. JCI Insight. 2021. “Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis.” doi.org/10.1172/jci.insight.146334
- Le HH, et al. EBioMedicine. 2021. “Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells.” doi.org/10.1016/j.ebiom.2021.103646
- Alameen AAM, et al. Naunyn Schmiedebergs Arch Pharmacol. 2026. “Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline.” doi.org/10.1007/s00210-026-05309-6
Regulatory status: Not an approved drug. Research material, RUO.
◆ A reference, not a recommendation
This page explains what FOXO4-DRI is and where it came from — the science and the story — not who should use anything, or how. These are research materials for laboratory research only; nothing here is medical, dosing, or treatment advice.
Research-use-only educational content. Factual overview; claims of clinical benefit are not implied.